AbbVie said on Monday it would buy biotech Apogee Therapeutics for $10.9 billion, in its largest buyout in more than five years to strengthen its next-gen immunology pipeline.
June 22, 2026 - 14:55
By Pharos Investment Advisors Comments are Off
AbbVie said on Monday it would buy biotech Apogee Therapeutics for $10.9 billion, in its largest buyout in more than five years to strengthen its next-gen immunology pipeline.
Regulated by Hellenic Capital Market Commission
with Registration Number 5/700/10.12.2014

Copyright 2023©. All Rights Reserved